Literature DB >> 18314572

Standardization of the clinical diagnosis of the dementia syndrome and its subtypes in a cross-national study: the Ni-Hon-Sea experience.

E B Larson1, S M McCurry, A B Graves, J D Bowen, M M Rice, W C McCormick, N Zee, A Homma, Y Imai, L White, K Masaki, H Petrovitch, W Ross, M Yamada, Y Mimori, H Sasaki.   

Abstract

BACKGROUND: Clinical investigators from Seattle, Honolulu, Tokyo, and Hiroshima participated in two standardization exercises in which data were collected on independent assessments. Exercises were conducted to evaluate the interobserver agreement on clinical diagnoses of dementia and dementia subtypes in a cross-national study of dementia prevalence and incidence rates in the United States and Japan.
METHOD: Fifteen clinicians from four participating sites assessed the diagnosis of 85 patients based on standardized summaries of clinical and diagnostic test data on each patient. Diagnostic guidelines and conventions were adopted on the basis of group consensus during standardization exercises.
RESULTS: Using DSM-III-R criteria, generally good levels of agreement for all dementia diagnostic categories occurred in both years. For most measures of diagnostic agreement, improvements were observed between the 1995 and 1996 standardization sessions. Interrater agreement was highest for discrimination between dementia and nondementia (1996 overall kappa, K = .90). The kappa values for dementia subtypes in 1996 ranged from .5 to .85, and for all sites combined the value was .67. For dementia subtypes, percent agreement was highest for vascular dementia and Alzheimer's disease, but was less reliable for other types of dementia.
CONCLUSIONS: Clinicians from different cultures and medical traditions can reliably use the DSM-III-R criteria to classify dementia cases in cross-national research. The interrater agreement on dementia and its subtypes improved after clear-cut guidelines for interpretation of diagnostic criteria were developed and followed.

Entities:  

Mesh:

Year:  1998        PMID: 18314572     DOI: 10.1093/gerona/53a.4.m313

Source DB:  PubMed          Journal:  J Gerontol A Biol Sci Med Sci        ISSN: 1079-5006            Impact factor:   6.053


  7 in total

1.  Fruit and vegetable juices and Alzheimer's disease: the Kame Project.

Authors:  Qi Dai; Amy R Borenstein; Yougui Wu; James C Jackson; Eric B Larson
Journal:  Am J Med       Date:  2006-09       Impact factor: 4.965

2.  Heterogeneity in 14-year Dementia Incidence Between Asian American Subgroups.

Authors:  Elizabeth R Mayeda; M Maria Glymour; Charles P Quesenberry; Rachel A Whitmer
Journal:  Alzheimer Dis Assoc Disord       Date:  2017 Jul-Sep       Impact factor: 2.703

3.  Passive case-finding for Alzheimer's disease and dementia in two U.S. communities.

Authors:  David S Knopman; Ronald C Petersen; Walter A Rocca; Eric B Larson; Mary Ganguli
Journal:  Alzheimers Dement       Date:  2011-01       Impact factor: 21.566

Review 4.  Clinical judgement by primary care physicians for the diagnosis of all-cause dementia or cognitive impairment in symptomatic people.

Authors:  Samuel T Creavin; Anna H Noel-Storr; Ryan J Langdon; Edo Richard; Alexandra L Creavin; Sarah Cullum; Sarah Purdy; Yoav Ben-Shlomo
Journal:  Cochrane Database Syst Rev       Date:  2022-06-16

5.  Incidence rates of dementia, Alzheimer disease, and vascular dementia in the Japanese American population in Seattle, WA: the Kame Project.

Authors:  Amy R Borenstein; Yougui Wu; James D Bowen; Wayne C McCormick; Jay Uomoto; Susan M McCurry; Gerard D Schellenberg; Eric B Larson
Journal:  Alzheimer Dis Assoc Disord       Date:  2014 Jan-Mar       Impact factor: 2.703

6.  Japanese-English language equivalence of the Cognitive Abilities Screening Instrument among Japanese-Americans.

Authors:  Laura E Gibbons; Susan McCurry; Kristoffer Rhoads; Kamal Masaki; Lon White; Amy R Borenstein; Eric B Larson; Paul K Crane
Journal:  Int Psychogeriatr       Date:  2008-10-24       Impact factor: 3.878

7.  Brain uptake and safety of Flutemetamol F 18 injection in Japanese subjects with probable Alzheimer's disease, subjects with amnestic mild cognitive impairment and healthy volunteers.

Authors:  Takami Miki; Hiroyuki Shimada; Jae-Seung Kim; Yasuji Yamamoto; Masakazu Sugino; Hisatomo Kowa; Kerstin Heurling; Michelle Zanette; Paul F Sherwin; Michio Senda
Journal:  Ann Nucl Med       Date:  2017-02-08       Impact factor: 2.668

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.